Nektar Therapeutics Files 8-K for Material Agreement

Ticker: NKTR · Form: 8-K · Filed: Apr 23, 2026 · CIK: 0000906709

Nektar Therapeutics 8-K Filing Summary
FieldDetail
CompanyNektar Therapeutics (NKTR)
Form Type8-K
Filed DateApr 23, 2026
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, filing

Related Tickers: NKTR

TL;DR

Nektar inked a new deal, filing an 8-K on 4/23/26. Details TBD.

AI Summary

On April 21, 2026, Nektar Therapeutics entered into a material definitive agreement, the details of which are not specified in this filing. The company also reported other events and filed financial statements and exhibits related to this agreement. The filing was accepted by the SEC on April 23, 2026.

Why It Matters

This filing indicates a significant new agreement for Nektar Therapeutics, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement's terms and potential impact introduces uncertainty.

Key Players & Entities

  • Nektar Therapeutics (company) — Filer of the 8-K report
  • 0000906709 (company) — CIK number for Nektar Therapeutics
  • 2026-04-21 (date) — Period of report for the 8-K filing
  • 2026-04-23 (date) — Filing date and acceptance date of the 8-K

FAQ

What is the nature of the material definitive agreement entered into by Nektar Therapeutics?

The filing does not specify the nature or terms of the material definitive agreement, only that one was entered into on April 21, 2026.

What are the specific items reported in this 8-K filing?

This 8-K filing includes Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).

When was this 8-K filing accepted by the SEC?

The 8-K filing was accepted by the SEC on April 23, 2026.

What is Nektar Therapeutics' mailing and business address?

Nektar Therapeutics' mailing and business address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158.

What is the CIK number for Nektar Therapeutics?

The CIK number for Nektar Therapeutics is 0000906709.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2026 regarding NEKTAR THERAPEUTICS (NKTR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.